Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Unituxin Dinutuximab Neuroblastoma Reimburse with clinical criteria and/or conditions Complete
Unituxin dinutuximab Neuroblastoma Reimburse with clinical criteria and/or conditions Complete
Uplizna inebilizumab Neuromyelitis optica spectrum disorders (NMOSD) Active
Uptravi Selexipag Pulmonary arterial hypertension (WHO class II and III) Reimburse with clinical criteria and/or conditions Complete
Vabysmo faricimab Diabetic Macular Edema Reimburse with clinical criteria and/or conditions Complete
Vabysmo faricimab Macular degeneration, age-related Reimburse with clinical criteria and/or conditions Complete
Vantas Histrelin acetate Cancer, prostate Do not list Complete
Vascepa icosapent ethyl Ischemic events in statin-treated patients Reimburse with clinical criteria and/or conditions Complete
Vectibix Panitumumab Metastatic Colorectal Cancer Reimburse with clinical criteria and/or conditions Complete
Vectibix Panitumumab Left Sided Metastatic Colorectal Cancer (mCRC) Do not reimburse Complete